KATP channel activators can partially suppress insulin secretion, are approved for the treatment of hyperinsulinemia, and would be useful to reduce the contribution of hyperinsulinemia to hyperphagia and obesity (Figure 1). This evidence concerns the gene INS and hyperinsulinism.